KRAS and leukemia: Huang X et al [23] reviewed in 2018 that IGF2BP1 was over-expressed in diverse types of cancers, including lung cancer, liver cancer, leukemia and many other diseases; this up-regulation showed cancer-promoting effect by stabilizing many mRNAs and non-coding RNAs, like KRAS, MYC, let-7 et al. Similarly, IGF2BP3 [24] was also highly expressed in a variety of cancers, promoting carcinogenesis through its RBP function.